Baseline patient characteristics
| All | nhVT | ICM | P value | |
| Procedures | 53 | 26 | 19 | |
| Patients | 47 | 23 | 16 | |
| Age, years | 57±15 | 48±13 | 70±9 | <0.001 |
| Sex: male | 36 (68) | 15 (58) | 14 (74) | 0.268 |
| Caucasian | 43 (81) | 18 (69) | 18 (95) | 0.035 |
| Asian | 3 (6) | 8 (31) | 1 (5) | |
| Hypertension | 14 (26) | 2 (8) | 10 (53) | 0.002 |
| Atrial fibrillation | 12 (23) | 1 (4) | 8 (42) | 0.002 |
| Diabetes | 4 (8) | 1 (4) | 2 (11) | 0.375 |
| Stroke | 0 | |||
| Left ventricular systolic dysfunction (LVEF <40%) | 21 (40) | 0 | 15 (79) | <0.001 |
| LVEF, % | 43±16 | 56±6 | 29±11 | 0.011 |
| Wall motion abnormalities | 22 (43) | 1 (4) | 17 (89) | <0.001 |
| Previous VT ablation | 5 (9) | 1 (4) | 3 (16) | 0.164 |
| Implantable cardioverter defibrillator implanted | 24 (45) | 0 | 17 (89) | <0.001 |
| Device therapies received | ||||
| ATP | 22 (92) | – | 16 (94) | |
| Shock | 16 (67) | – | 13 (76) | |
| Beta-blocker | 48 (91) | 23 (88) | 19 (100) | 0.125 |
| Amiodarone | 23 (43) | 1 (4) | 17 (89) | <0.001 |
| Duration of amiodarone, median (IQR) months | 12 (2–23) | 12 | 9 (1–24) | |
| Mexiletine | 6 (11) | 0 | 5 (26) | 0.006 |
| Verapamil | 4 (8) | 4 (15) | 0 | 0.073 |
| Flecainide | 2 (4) | 2 (8) | 0 | 0.216 |
| Anticoagulation | 21 (39) | 6 (23) | 10 (53) | 0.041 |
| Warfarin | 13 (25) | 5 (19) | 7 (37) | |
| Apixaban | 6 (11) | 1 (4) | 3 (16) | |
| Dabigatran | 1 (2) | 0 | 0 | |
| Edoxaban | 1 (2) | 0 | 0 |
Values expressed as mean±SD or frequency (%) unless otherwise specified.
ATP, antitachycardia pacing; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; nhVT, normal heart VT; VT, ventricular tachycardia.